Duke cancer care in Wake County
Treatment Terms Cancer Anal cancer Bile duct cancer Bladder cancer Breast cancer Colon cancer Esophageal cancer Gallbladder cancer Kidney cancer Liver cancer Lung cancer Oral cancer Ovarian cancer Pancreatic cancer Prostate cancer Rectal cancer Skin cancers Skull base tumor Spine cancer Stomach cancer Testicular cancer Throat and voice box cancer Thyroid cancer Tracheal cancer Uterine cancer Vaginal cancer and vulvar cancer Additional SEO Keywords cancer imaging and treatment in Cary and Raleigh SEO Meta Description Everything you need for your cancer diagnosis and treatment in Cary, Raleigh Author Debbe Geiger Sub-Title Access to care, technology and clinical trials closer to home Overview If you're a Wake County resident, you don't have to travel far for your cancer care. Everything you need, including the latest diagnostic imaging technology, cancer treatment advances, cancer clinical trials, and cancer support, is located conveniently near you at three Duke cancer treatment centers in Cary and Raleigh. Content Blocks Header Cancer treatment closer to your Wake County home Content The new Duke Cancer Center locations in Cary and Raleigh provide Wake County residents with more convenient access to the complete array of Duke cancer services and expert...
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Yanhua Liu, Yang Li, Shanshan Dong, Lu Han, Ruixin Guo, Yourong Fu, Shenghu Zhang, Jianqiu Chen
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Publication date: January 2021Source: Urology Case Reports, Volume 34Author(s): Nina Al-Saadi, Safa Al-Musawi, Yousuf Khan, Daben Dawam
Publication date: Available online 10 October 2020Source: European UrologyAuthor(s): Stanley Weng, Renzo G. DiNatale, Andrew Silagy, Roy Mano, Kyrollis Attalla, Mahyar Kashani, Kate Weiss, Nicole E. Benfante, Andrew G. Winer, Jonathan A. Coleman, Victor E. Reuter, Paul Russo, Ed Reznik, Satish K. Tickoo, A. Ari Hakimi
Publication date: Available online 10 October 2020Source: European Journal of Surgical OncologyAuthor(s): Tetsutaro Miyoshi, Satoshi Yamaguchi, Hiroshi Fujimoto, Shigeru Yoshioka, Masayuki Shiobara, Kazuo Wakatsuki, Kosuke Suda, Kotaro Miyazawa, Toshiaki Aida, Yoshihiro Watanabe, Masayuki Ohtsuka
Authors: Matti B, Zargar-Shoshtari K Abstract Prostate cancer represents a significant health burden worldwide. The cancer incidence had substantially increased since the introduction of prostate specific antigen (PSA) in cancer screening. This had led to considerable debates among health professionals and epidemiologists, since PSA as a screening tool seemed to be far from perfect. In New Zealand, the controversy was quite prominent in the last three decades, with some advocating the benefits of screening, while others concerned regarding the risk of harms. With the absence of an organised screening programme and ...
CONCLUSION: This study found that childhood cancer survivors in New Zealand had a high prevalence of developmental dental abnormalities and it identified potential risk factors related to their cancer treatment. Inequitable access to oral rehabilitation for this patient group argues for a mechanism for consistent improved access to publicly funded dental care across district health boards in New Zealand. PMID: 33032302 [PubMed - in process]
Authors: Zarrabi A, Mark S PMID: 33032299 [PubMed - in process]
Publication date: Available online 9 October 2020Source: European Journal of RadiologyAuthor(s): Yan Huang, Qin Xiao, Yiqun Sun, Qin Li, Simin Wang, Yajia Gu
Authors: Peng C, Cohen DJ Abstract INTRODUCTION: Esophageal squamous cancer remains an important cause of mortality worldwide with two new immunotherapy drugs recently approved for metastatic disease. AREAS COVERED: The authors review the epidemiology and genomics of esophageal squamous cell carcinoma. They also examine prior trials involving targeted agents under investigation as well immunotherapies that have been approved and novel combinations. EXPERT OPINION: Great advances have been made in characterizing the molecular changes in esophageal carcinoma. However, relatively few drugs have shown benefit i...
More News: Anal Cancer | Bile | Bile Duct Cancer | Bladder Cancer | Blogging | Breast Cancer | Cancer | Cancer & Oncology | Cancer of the Uterus | Chemotherapy | Cholangiocarcinoma | Clinical Trials | Colon Cancer | Colorectal Cancer | Esophagus Cancer | External Beam Therapy | Gallbladder Cancer | Gastric (Stomach) Cancer | Health | Hematology | Hospitals | Kidney Cancer | Learning | Liver | Lung Cancer | Mammography | Oral Cancer | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Prostate Cancer | Radiation Therapy | Rectal Cancers | Skin | Study | Testicular Cancer | Thyroid | Thyroid Cancer | Tracheal Cancer | Ultrasound | Universities & Medical Training | Urology & Nephrology | Vaginal Cancer | Vulvar Cancer